Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease

被引:20
|
作者
Gomez-Pinedo, Ulises [1 ]
Galan, Lucia [2 ]
Matias-Guiu, Jordi A. [2 ]
Pytel, Vanesa [1 ,2 ]
Moreno, Teresa [2 ]
Guerrero-Sola, Antonio [2 ]
Matias-Guiu, Jorge [1 ,2 ]
机构
[1] Univ Complutense Madrid, Lab Neurobiol, IdISSC, Hosp Clin San Carlos,Inst Neurosci, Madrid, Spain
[2] Univ Complutense Madrid, Dept Neurol, IdISSC, Hosp Clin San Carlos,Inst Neurosci, Madrid, Spain
来源
FRONTIERS IN NEUROSCIENCE | 2019年 / 13卷
关键词
ALS; Notch; NICD; APP; ADAM10; ADAM17; BACE1; hippocampal neurogenesis; AMYOTROPHIC-LATERAL-SCLEROSIS; INTRACELLULAR DOMAIN; TSPANC8; TETRASPANINS; ADULT; APP; PROTEIN; ACTIVATION; PATHWAY; ALZHEIMERS; CLEAVAGE;
D O I
10.3389/fnins.2019.00302
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction: The Notch signalling pathway regulates neuronal survival. It has some similarities with the APP signalling pathway, and competes with the latter for alpha- and gamma-secretase proteolytic complexes. The objective of this study was to study the Notch signalling pathway in the hippocampi of patients with motor neuron disease. Methods: We studied biological material from the autopsies of 12 patients with motor neuron disease and 4 controls. We analysed the molecular markers of the Notch and APP signalling pathways, TDP43, tau, and markers of neurogenesis. Results and Conclusion: Low NICD expression suggests Notch signalling pathway inactivation in neurons. Inactivation of the pathway despite increased Notch1 expression is associated with a lack of alpha-secretase expression. We observed increased beta-secretase expression associated with activation of the amyloid cascade of APP, leading to increases in amyloid-beta and AICD peptides and decreased levels of Fe65. Inactivation of the Notch signalling pathway is an important factor in decreased neurogenic response in the hippocampi of patients with amyotrophic lateral sclerosis.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] MOTOR NEURON DISEASE
    GUILOFF, RJ
    CURRENT OPINION IN NEUROLOGY AND NEUROSURGERY, 1988, 1 (04): : 627 - 632
  • [22] MOTOR NEURON DISEASE
    FARN, KT
    BRITISH MEDICAL JOURNAL, 1980, 280 (6216): : 791 - 792
  • [23] Motor neuron disease
    Sailler, L
    Madaule, S
    Voisin, T
    Astudillo, L
    Arne-Bes, MV
    Arlet, P
    REVUE DE MEDECINE INTERNE, 2003, 24 : 266S - 267S
  • [24] Blood glutamate levels in patients with motor neuron disease
    Babu, GN
    Bawari, M
    Mathur, VN
    Kalita, J
    Misra, UK
    CLINICA CHIMICA ACTA, 1998, 273 (02) : 195 - 200
  • [25] Factors affecting survival in patients with motor neuron disease
    Kuric, T. Gilman
    Tamse, J.
    Misevic, S.
    Poljak, L. Knezevic
    Popovic, Z.
    Tomic, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 624 - 624
  • [26] Burden of Nasal Symptoms in Motor Neuron Disease patients
    Talty, M.
    Gargoum, F.
    Rutherford, R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S37 - S37
  • [27] EYELID APRAXIA IN PATIENTS WITH MOTOR-NEURON DISEASE
    ABE, K
    FUJIMURA, H
    TATSUMI, C
    TOYOOKA, K
    YORIFUJI, S
    YANAGIHARA, T
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 59 (06): : 629 - 632
  • [28] Reviewing evidences on the management of patients with motor neuron disease
    Lee, C. N.
    HONG KONG MEDICAL JOURNAL, 2012, 18 (01) : 48 - 55
  • [29] FACEMASK SPIROMETRY IN PATIENTS WITH BULBAR MOTOR NEURON DISEASE
    Khaliq, A. A.
    Smith, I. E.
    THORAX, 2009, 64 : A44 - A44
  • [30] Evaluation and rehabilitation of patients with adult motor neuron disease
    Francis, K
    Bach, JR
    DeLisa, JA
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1999, 80 (08): : 951 - 963